<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="pmcid: 7073089 doi: 10.3390/ijms21041376ijms-21-01376 : Review Potential Therapeutic Approaches Against" exact="Brain" post="Diseases Associated with Cytomegalovirus Infections https://orcid.org/0000-0002-7009-5338WangShao-Cheng12†https://orcid.org/0000-0002-4263-527XChenShiu-Jau34†https://orcid.org/0000-0002-6592-2845ChenYuan-Chuan5*[1], WShaocheng@gmail.com[2], [3], chenshiujau@gmail.com[4],"/>
 <result pre="7073089 doi: 10.3390/ijms21041376ijms-21-01376 : Review Potential Therapeutic Approaches Against Brain" exact="Diseases" post="Associated with Cytomegalovirus Infections https://orcid.org/0000-0002-7009-5338WangShao-Cheng12†https://orcid.org/0000-0002-4263-527XChenShiu-Jau34†https://orcid.org/0000-0002-6592-2845ChenYuan-Chuan5*[1], WShaocheng@gmail.com[2], [3], chenshiujau@gmail.com[4], [5],"/>
 <result pre=": Review Potential Therapeutic Approaches Against Brain Diseases Associated with" exact="Cytomegalovirus Infections" post="https://orcid.org/0000-0002-7009-5338WangShao-Cheng12†https://orcid.org/0000-0002-4263-527XChenShiu-Jau34†https://orcid.org/0000-0002-6592-2845ChenYuan-Chuan5*[1], WShaocheng@gmail.com[2], [3], chenshiujau@gmail.com[4], [5], *Correspondence: yuchuan1022@gmail.com; Tel.: +886-939212068"/>
 <result pre="Review Potential Therapeutic Approaches Against Brain Diseases Associated with Cytomegalovirus" exact="Infections" post="https://orcid.org/0000-0002-7009-5338WangShao-Cheng12†https://orcid.org/0000-0002-4263-527XChenShiu-Jau34†https://orcid.org/0000-0002-6592-2845ChenYuan-Chuan5*[1], WShaocheng@gmail.com[2], [3], chenshiujau@gmail.com[4], [5], *Correspondence: yuchuan1022@gmail.com; Tel.: +886-939212068"/>
 <result pre="especially for immunologically comprised patients. CMV may cause opportunistic infections," exact="congenital" post="infections, and brain diseases (e.g., mental retardation and glioblastoma)."/>
 <result pre="comprised patients. CMV may cause opportunistic infections, congenital infections, and" exact="brain diseases" post="(e.g., mental retardation and glioblastoma). The etiology of brain"/>
 <result pre="may cause opportunistic infections, congenital infections, and brain diseases (e.g.," exact="mental retardation" post="and glioblastoma). The etiology of brain diseases associated with"/>
 <result pre="brain diseases (e.g., mental retardation and glioblastoma). The etiology of" exact="brain diseases" post="associated with human CMV (HCMV) infections is usually complex"/>
 <result pre="The etiology of brain diseases associated with human CMV (HCMV)" exact="infections" post="is usually complex and it is particularly difficult to"/>
 <result pre="is particularly difficult to treat because HCMV has a life-long" exact="infection" post="in its hosts, high mutation rate, and latent infections."/>
 <result pre="drug discovery recently, current drugs used for treating active CMV" exact="infections" post="are still limited in efficacy due to side effects,"/>
 <result pre="current drugs used for treating active CMV infections are still" exact="limited" post="in efficacy due to side effects, toxicity, and viral"/>
 <result pre="still limited in efficacy due to side effects, toxicity, and" exact="viral" post="resistance. Fortunately, letermovir which targets the HCMV terminase complex"/>
 <result pre="with fewer adverse reactions has been approved to treat CMV" exact="infections" post="in humans. The researchers are focusing on developing approaches"/>
 <result pre="are focusing on developing approaches against both productive and latent" exact="infections" post="of CMV. The gene or RNA targeting approaches including"/>
 <result pre="of CMV. The gene or RNA targeting approaches including the" exact="external" post="guide sequences (EGSs)-RNase, the clustered regularly interspaced short palindromic"/>
 <result pre="including the external guide sequences (EGSs)-RNase, the clustered regularly interspaced" exact="short" post="palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system and transcription"/>
 <result pre="transcription activator-like effector nucleases (TALENs) are being investigated to remove" exact="acute" post="and/or latent CMV infections. For the treatment of glioblastoma,"/>
 <result pre="expecting to have a great impact on the therapy of" exact="brain diseases" post="associated with CMV infections. cytomegalovirus brain disease mental retardation"/>
 <result pre="the therapy of brain diseases associated with CMV infections. cytomegalovirus" exact="brain disease" post="mental retardation glioblastoma gene/RNA targeting approach vaccine therapy immunotherapy"/>
 <result pre="therapy of brain diseases associated with CMV infections. cytomegalovirus brain" exact="disease" post="mental retardation glioblastoma gene/RNA targeting approach vaccine therapy immunotherapy"/>
 <result pre="of brain diseases associated with CMV infections. cytomegalovirus brain disease" exact="mental retardation" post="glioblastoma gene/RNA targeting approach vaccine therapy immunotherapy 1. Introduction"/>
 <result pre="diseases associated with CMV infections. cytomegalovirus brain disease mental retardation" exact="glioblastoma" post="gene/RNA targeting approach vaccine therapy immunotherapy 1. Introduction 1.1."/>
 <result pre="glioblastoma gene/RNA targeting approach vaccine therapy immunotherapy 1. Introduction 1.1." exact="Brain" post="Disease The brain is one’s body control center which"/>
 <result pre="gene/RNA targeting approach vaccine therapy immunotherapy 1. Introduction 1.1. Brain" exact="Disease" post="The brain is one’s body control center which controls"/>
 <result pre="different things such as sensation, memory, activity, and even personality." exact="Brain" post="diseases include any conditions or disabilities that affect the"/>
 <result pre="that affect the brain, and major types are brain injury," exact="mental disorder," post="neurodegenerative disease, mental retardation, and brain tumor (Table 1,"/>
 <result pre="and major types are brain injury, mental disorder, neurodegenerative disease," exact="mental retardation," post="and brain tumor (Table 1, [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15]). 1.2. Cytomegalovirus Overview"/>
 <result pre="are brain injury, mental disorder, neurodegenerative disease, mental retardation, and" exact="brain tumor" post="(Table 1, [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15]). 1.2. Cytomegalovirus Overview There are nine"/>
 <result pre="brain injury, mental disorder, neurodegenerative disease, mental retardation, and brain" exact="tumor" post="(Table 1, [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15]). 1.2. Cytomegalovirus Overview There are nine"/>
 <result pre="human herpesvirus (HHV) species known to cause human diseases, including" exact="herpes" post="simplex virus-1(HSV-1, HHV-1), herpes simplex virus-2 (HSV-2, HHV-2), varicella"/>
 <result pre="known to cause human diseases, including herpes simplex virus-1(HSV-1, HHV-1)," exact="herpes" post="simplex virus-2 (HSV-2, HHV-2), varicella zoster virus (VZV, HHV-3),"/>
 <result pre="including herpes simplex virus-1(HSV-1, HHV-1), herpes simplex virus-2 (HSV-2, HHV-2)," exact="varicella" post="zoster virus (VZV, HHV-3), Epstein-Barr virus (EBV, HHV-4), cytomegalovirus"/>
 <result pre="herpes simplex virus-1(HSV-1, HHV-1), herpes simplex virus-2 (HSV-2, HHV-2), varicella" exact="zoster" post="virus (VZV, HHV-3), Epstein-Barr virus (EBV, HHV-4), cytomegalovirus (CMV,"/>
 <result pre="encode regulatory proteins; (2) early genes, which encode enzymes for" exact="viral" post="DNA replication; (3) late genes, which encode structural proteins"/>
 <result pre="DNA replication; (3) late genes, which encode structural proteins for" exact="infectious" post="viral particles (virions) assembly. HCMV may cause mild or"/>
 <result pre="replication; (3) late genes, which encode structural proteins for infectious" exact="viral" post="particles (virions) assembly. HCMV may cause mild or subclinical"/>
 <result pre="healthy and immunocompetent adults; however, it can result in opportunistic" exact="infections" post="in individuals whose immune system is compromised or immature"/>
 <result pre="and causes multiple diseases such as pneumonitis, retinitis, gastrointestinal diseases," exact="vascular" post="disorder, mental retardation, mucoepidermoid carcinoma, severe cytomegalic inclusion disease"/>
 <result pre="multiple diseases such as pneumonitis, retinitis, gastrointestinal diseases, vascular disorder," exact="mental retardation," post="mucoepidermoid carcinoma, severe cytomegalic inclusion disease of the neonate"/>
 <result pre="such as pneumonitis, retinitis, gastrointestinal diseases, vascular disorder, mental retardation," exact="mucoepidermoid carcinoma," post="severe cytomegalic inclusion disease of the neonate [20,21,22,23]. CMV"/>
 <result pre="diseases, vascular disorder, mental retardation, mucoepidermoid carcinoma, severe cytomegalic inclusion" exact="disease" post="of the neonate [20,21,22,23]. CMV life cycle begins as"/>
 <result pre="host cell surface. For a lytic pathway, following attachment of" exact="viral" post="envelope glycoproteins to host cell membrane receptors, the virions"/>
 <result pre="enter host cells by receptor-mediated endocytosis and membrane fusion. The" exact="viral" post="capsid breaks down to release DNA genome to take"/>
 <result pre="make new virions. CMV express lytic genes to demonstrate a" exact="symptomatic" post="infection in hosts [24]. Alternatively, CMV may go into"/>
 <result pre="new virions. CMV express lytic genes to demonstrate a symptomatic" exact="infection" post="in hosts [24]. Alternatively, CMV may go into a"/>
 <result pre="a latent infection, referring as the episomal latency in which" exact="viral" post="DNA is episomal or tethered to host cell chromosomes"/>
 <result pre="The long-term latency in hosts is usually asymptomatic, though the" exact="primary" post="infection is not necessarily asymptomatic. When CMV are stimulated"/>
 <result pre="long-term latency in hosts is usually asymptomatic, though the primary" exact="infection" post="is not necessarily asymptomatic. When CMV are stimulated by"/>
 <result pre="is suppressed, the dormant viruses can reactivate to start producing" exact="viral" post="progeny to cause illness, denoted as the lytic life"/>
 <result pre="graft rejection in patients undergoing organ transplantation [27]. 2. CMV" exact="Infection" post="2.1. Congenital Infection Because CMV can be transmitted by"/>
 <result pre="in patients undergoing organ transplantation [27]. 2. CMV Infection 2.1." exact="Congenital" post="Infection Because CMV can be transmitted by the close"/>
 <result pre="patients undergoing organ transplantation [27]. 2. CMV Infection 2.1. Congenital" exact="Infection" post="Because CMV can be transmitted by the close interpersonal"/>
 <result pre="by the close interpersonal contact such as saliva, semen, urine," exact="breast" post="milk, or vertical transmission (viruses pass the placenta and"/>
 <result pre="infect the fetus) [28,29] which is the leading cause of" exact="congenital" post="infection [30,31,32,33]. Congenital CMV infection is both inherent infection"/>
 <result pre="the fetus) [28,29] which is the leading cause of congenital" exact="infection" post="[30,31,32,33]. Congenital CMV infection is both inherent infection and"/>
 <result pre="[28,29] which is the leading cause of congenital infection [30,31,32,33]." exact="Congenital" post="CMV infection is both inherent infection and intrauterine infection"/>
 <result pre="is the leading cause of congenital infection [30,31,32,33]. Congenital CMV" exact="infection" post="is both inherent infection and intrauterine infection [34,35]. Intrauterine"/>
 <result pre="of congenital infection [30,31,32,33]. Congenital CMV infection is both inherent" exact="infection" post="and intrauterine infection [34,35]. Intrauterine transmission may occur in"/>
 <result pre="[30,31,32,33]. Congenital CMV infection is both inherent infection and intrauterine" exact="infection" post="[34,35]. Intrauterine transmission may occur in mothers without immune"/>
 <result pre="preexisting antibodies against CMV either by the reactivation of previous" exact="infections" post="or by the infection of a different viral strain"/>
 <result pre="either by the reactivation of previous infections or by the" exact="infection" post="of a different viral strain (non-primary infection) [36]. A"/>
 <result pre="of previous infections or by the infection of a different" exact="viral" post="strain (non-primary infection) [36]. A mother can only transmit"/>
 <result pre="only transmit viruses to a neonate if she is undergoing" exact="primary" post="infection or robust reactivation. Most of congenital infections are"/>
 <result pre="transmit viruses to a neonate if she is undergoing primary" exact="infection" post="or robust reactivation. Most of congenital infections are asymptomatic"/>
 <result pre="she is undergoing primary infection or robust reactivation. Most of" exact="congenital" post="infections are asymptomatic (85–90%) and some present with clinically"/>
 <result pre="is undergoing primary infection or robust reactivation. Most of congenital" exact="infections" post="are asymptomatic (85–90%) and some present with clinically apparent"/>
 <result pre="and some present with clinically apparent symptoms (10–15%), but the" exact="symptomatic" post="disease usually emerges after primary maternal infection in pregnancy"/>
 <result pre="some present with clinically apparent symptoms (10–15%), but the symptomatic" exact="disease" post="usually emerges after primary maternal infection in pregnancy [37,38]."/>
 <result pre="apparent symptoms (10–15%), but the symptomatic disease usually emerges after" exact="primary" post="maternal infection in pregnancy [37,38]. The morbidity risk in"/>
 <result pre="(10–15%), but the symptomatic disease usually emerges after primary maternal" exact="infection" post="in pregnancy [37,38]. The morbidity risk in newborns is"/>
 <result pre="[37,38]. The morbidity risk in newborns is increased because the" exact="central nervous system" post="(CNS) is damaged, resulting in delays in neurodevelopment, loss"/>
 <result pre="loss in hearing, and impairment in eyesight. 2.2. Sequelaes CMV" exact="infection" post="is mostly asymptomatic among the general population; however, around"/>
 <result pre="general population; however, around 10% to 15% of infants with" exact="congenital" post="CMV infections may be at risk of sequelaes such"/>
 <result pre="however, around 10% to 15% of infants with congenital CMV" exact="infections" post="may be at risk of sequelaes such as mental"/>
 <result pre="CMV infections may be at risk of sequelaes such as" exact="mental retardation," post="jaundice, hepatosplenomegaly, microcephaly, hearing impairment, and thrombocytopenia [39,40,41,42]. Among"/>
 <result pre="such as mental retardation, jaundice, hepatosplenomegaly, microcephaly, hearing impairment, and" exact="thrombocytopenia" post="[39,40,41,42]. Among these sequelaes, the most devastating one is"/>
 <result pre="because CNS injury is irreversible and persists for life, including" exact="mental retardation," post="seizures, hearing loss, ocular abnormalities, and cognitive impairment [43,44,45]."/>
 <result pre="is irreversible and persists for life, including mental retardation, seizures," exact="hearing loss," post="ocular abnormalities, and cognitive impairment [43,44,45]. This means the"/>
 <result pre="and persists for life, including mental retardation, seizures, hearing loss," exact="ocular" post="abnormalities, and cognitive impairment [43,44,45]. This means the asymptomatic"/>
 <result pre="life, including mental retardation, seizures, hearing loss, ocular abnormalities, and" exact="cognitive impairment" post="[43,44,45]. This means the asymptomatic newborns with congenital CMV"/>
 <result pre="and cognitive impairment [43,44,45]. This means the asymptomatic newborns with" exact="congenital" post="CMV infection still have an increased risk for long-term"/>
 <result pre="impairment [43,44,45]. This means the asymptomatic newborns with congenital CMV" exact="infection" post="still have an increased risk for long-term sequelae, especially,"/>
 <result pre="infection still have an increased risk for long-term sequelae, especially," exact="mental retardation" post="and sensorineural hearing loss (SNHL) [46,47,48,49], making CMV the"/>
 <result pre="an increased risk for long-term sequelae, especially, mental retardation and" exact="sensorineural" post="hearing loss (SNHL) [46,47,48,49], making CMV the leading nonhereditary"/>
 <result pre="increased risk for long-term sequelae, especially, mental retardation and sensorineural" exact="hearing loss" post="(SNHL) [46,47,48,49], making CMV the leading nonhereditary cause of"/>
 <result pre="leading nonhereditary cause of SNHL [42,50]. 2.3. Correlation between CMV" exact="Infection" post="and Brain Diseases CNS diseases induced by CMV infections"/>
 <result pre="cause of SNHL [42,50]. 2.3. Correlation between CMV Infection and" exact="Brain" post="Diseases CNS diseases induced by CMV infections including encephalitis"/>
 <result pre="of SNHL [42,50]. 2.3. Correlation between CMV Infection and Brain" exact="Diseases" post="CNS diseases induced by CMV infections including encephalitis and"/>
 <result pre="CMV Infection and Brain Diseases CNS diseases induced by CMV" exact="infections" post="including encephalitis and transverse myelitis are mostly found in"/>
 <result pre="and Brain Diseases CNS diseases induced by CMV infections including" exact="encephalitis" post="and transverse myelitis are mostly found in immunocompromise patients."/>
 <result pre="CNS diseases induced by CMV infections including encephalitis and transverse" exact="myelitis" post="are mostly found in immunocompromise patients. CMV polymerase chain"/>
 <result pre="(CSF) are available for the determination of the etiology. CMV" exact="viral" post="loads in CSF and urine may be useful for"/>
 <result pre="evaluating the response for the treatment and clinical outcomes [51]." exact="Congenital" post="CMV infections can lead to mental retardation in newborns,"/>
 <result pre="response for the treatment and clinical outcomes [51]. Congenital CMV" exact="infections" post="can lead to mental retardation in newborns, but it"/>
 <result pre="and clinical outcomes [51]. Congenital CMV infections can lead to" exact="mental retardation" post="in newborns, but it is certainly not a main"/>
 <result pre="Glioblastoma (GBM) is one of the most common and devastating" exact="brain tumors" post="in adults [52]. Previous studies showed that some malignant"/>
 <result pre="brain tumors in adults [52]. Previous studies showed that some" exact="malignant" post="GBMs express the CMV-associated proteins including the immediately early"/>
 <result pre="CMV-associated proteins including the immediately early gene-1 product and the" exact="lower" post="matrix phosphoprotein 65 (pp65) which is encoded by unique"/>
 <result pre="and suggested that HCMV may play an active role in" exact="glioma" post="pathogenesis [53]. HCMV can induce GBM formation in vitro"/>
 <result pre="no definite evidence on its ubiquity and its role in" exact="tumor" post="formation [54]. In animal studies, murine CMV (MCMV) has"/>
 <result pre="for GBM therapy. 3. CMV Medication Current drugs for anti-CMV" exact="infections" post="include the inhibitors of viral DNA polymerase, such as"/>
 <result pre="Medication Current drugs for anti-CMV infections include the inhibitors of" exact="viral" post="DNA polymerase, such as ganciclovir, valganciclovir, cidofovir, and foscarnet."/>
 <result pre="mainly used for both preemptive therapy and prophylaxis of CMV" exact="infections" post="in solid organ transplant (SOT) patients, but their bone"/>
 <result pre="cell transplant [56]. Cidofovir is employed almost exclusively to treat" exact="CMV retinitis" post="in patients with acquired immunodeficiency syndrome (AIDS) [57]. Foscarnet"/>
 <result pre="transplant [56]. Cidofovir is employed almost exclusively to treat CMV" exact="retinitis" post="in patients with acquired immunodeficiency syndrome (AIDS) [57]. Foscarnet"/>
 <result pre="employed almost exclusively to treat CMV retinitis in patients with" exact="acquired" post="immunodeficiency syndrome (AIDS) [57]. Foscarnet is principally used to"/>
 <result pre="almost exclusively to treat CMV retinitis in patients with acquired" exact="immunodeficiency" post="syndrome (AIDS) [57]. Foscarnet is principally used to treat"/>
 <result pre="exclusively to treat CMV retinitis in patients with acquired immunodeficiency" exact="syndrome" post="(AIDS) [57]. Foscarnet is principally used to treat ganciclovir-resistant"/>
 <result pre="(AIDS) [57]. Foscarnet is principally used to treat ganciclovir-resistant CMV" exact="infections" post="in patients with AIDS or in transplant recipients [58,59]."/>
 <result pre="5 years. Valnoctamide, a neuroactive mood stabilizer which inhibits CMV" exact="infection" post="in developing brain and attenuates neurobehavioral dysfunctions, was shown"/>
 <result pre="and brincidofovir) are also potentially applied for the treatment of" exact="brain disease" post="associated with CMV infections. 3.1. Letermovir Letermovir has been"/>
 <result pre="brincidofovir) are also potentially applied for the treatment of brain" exact="disease" post="associated with CMV infections. 3.1. Letermovir Letermovir has been"/>
 <result pre="the European Medicines Agency (EMA) for the prophylaxis of CMV" exact="infections" post="in patients [62]. The drug was tested in CMV"/>
 <result pre="patients who had organ transplantation or human immunodeficient virus (HIV)" exact="infections" post="[63]. It has been clinically applied for CMV prophylaxis"/>
 <result pre="CMV antiviral agents such as administration orally, mild toxicity without" exact="myelotoxicity" post="and nephrotoxicity [67,68], and targeting of the CMV terminase"/>
 <result pre="Conventional anti-CMV drugs which target the UL54 DNA polymerase are" exact="limited" post="in safety and efficacy because of their nephrotoxicity and"/>
 <result pre="limited in safety and efficacy because of their nephrotoxicity and" exact="viral" post="resistance. In addition to less toxicity for kidney and"/>
 <result pre="is also promising to be used in the treatment of" exact="brain diseases" post="associated with CMV infections. 3.2. Maribavir Maribavir is a"/>
 <result pre="compound which can be given orally. The drug targets the" exact="viral" post="kinase UL97 which is crucial for the formation of"/>
 <result pre="viral kinase UL97 which is crucial for the formation of" exact="viral" post="teguments and assembly complexes for virion releasing [62]. However,"/>
 <result pre="transplant (HCT) or SOT recipients with refractory or resistant CMV" exact="infections" post="in a clinical phase II and double-blind clinical trial"/>
 <result pre="in HCT and SOT recipients with refractory or resistant CMV" exact="infections" post="is still ongoing [70,71]. 3.3. Brincidofovir Brincidofovir (CMX001) is"/>
 <result pre="developed for the treatment of CMV, adenovirus, smallpox, and ebolavirus" exact="infections" post="[72]. Marty et al. significantly reduced CMV viremia in"/>
 <result pre="mg BIW only caused dose-limiting toxicity. This cohort experienced severe" exact="diarrhea" post="and gastrointestinal acute graft-versus-host diseases. These findings promoted the"/>
 <result pre="caused dose-limiting toxicity. This cohort experienced severe diarrhea and gastrointestinal" exact="acute" post="graft-versus-host diseases. These findings promoted the performance of a"/>
 <result pre="tolerability and safety of brincidofovir was acceptable and no dose-dependent" exact="myelotoxicity" post="or nephrotoxicity was observed. By these results, they continued"/>
 <result pre="phase III trial for the prevention of clinically significant CMV" exact="infection" post="in allogeneic HCT recipients. However, the results showed that"/>
 <result pre="transcription activator-like effectors nucleases (TALENs) and the clustered regularly interspaced" exact="short" post="palindromic repeats (CRISPRs)/Cas9 nuclease system potentially function as effective"/>
 <result pre="nuclease system potentially function as effective therapeutic approaches to treat" exact="brain diseases" post="associated with CMV infections through designing a specific DNA"/>
 <result pre="effective therapeutic approaches to treat brain diseases associated with CMV" exact="infections" post="through designing a specific DNA or RNA sequence that"/>
 <result pre="specific DNA or RNA sequence that target genes required for" exact="viral" post="growth. Though CRISPR/Cas9 and TALENs are both promisingly effective"/>
 <result pre="clinical application, it is required to have accurate modification of" exact="viral" post="genomes for avoiding off-target mutation in humans. 4.1. EGS-RNase"/>
 <result pre="capsid scaffolding protein (mCSP) and assemblin which is essential for" exact="viral" post="progeny production. In vitro, the EGS variant was 60"/>
 <result pre="cells, the variant reduced mCSP expression by 92% and decreased" exact="viral" post="growth by 8000 folds. In MCMV-infected mice, the EGS"/>
 <result pre="EGS originating from a natural tRNA in reducing mCSP expression," exact="viral" post="production, and mouse mortality. The results showed that engineered"/>
 <result pre="suggested its possiblility for engineered EGS variants to treat MCMV" exact="infections" post="[77]. Li and Liu et al. used an in"/>
 <result pre="gene expression reduction by about 98% and 73%, and the" exact="viral" post="growth was inhibited by about 10,000 and 200 folds,"/>
 <result pre="in the inhibition of the expression of HCMV genes and" exact="viral" post="growth, compared with the natural EGS [79]. 4.2. CRISPR/Cas9"/>
 <result pre="considered as a potential approach applied to fight against herpesvirus" exact="infections" post="[80]. Van Diemen et al. set out to combat"/>
 <result pre="al. set out to combat both productive and latent HCMV" exact="infections" post="using CRISPR/Cas9 to target genes essential for virus growth"/>
 <result pre="effective inhibition of HCMV replication by targeting sgRNAs to essential" exact="viral" post="genes UL57 and UL70 than the nonessential genes US7"/>
 <result pre="effective CRISPR/Cas9 to target HCMV during both productive and latent" exact="infections" post="[82]. Gergen et al. designed two CRISPR/Cas9 systems which"/>
 <result pre="and a concomitant reduction of immediate early gene expression in" exact="primary" post="fibroblasts. The singleplex strategy caused 50% of insertions and/or"/>
 <result pre="strategy caused 50% of insertions and/or deletions (indels) in the" exact="viral" post="genome were shown in U-251 MG cells, resulting in"/>
 <result pre="gene and thereby inhibited their expression. The results revealed that" exact="viral" post="genome replication and late protein expression were reduced by"/>
 <result pre="able to target the HCMV UL122/123 gene specifically and inhibit" exact="viral" post="replication efficiently [83]. 4.3. TALENs Transcription activator-like effectors (TALEs)"/>
 <result pre="chemotherapy with temozolomide [88,89]. Activation of the immune system against" exact="tumor" post="cells based on vaccine therapy/immunotherapy contribute to facilitate survival"/>
 <result pre="CMV has emerged as an immunologic target in GBM if" exact="tumor" post="cells have been shown to express the CMV-associated proteins"/>
 <result pre="pp65 RNA-transfected dendritic cells (DC) target and remove autologous GBM" exact="tumor" post="cells [92]. CMV pp65-specific immune responses were elicited in"/>
 <result pre="an antigen-specific manner, CMV pp65-specific T cells lyse autologous and" exact="primary" post="GBM tumor cells. Moreover, T cells expanded in vitro"/>
 <result pre="manner, CMV pp65-specific T cells lyse autologous and primary GBM" exact="tumor" post="cells. Moreover, T cells expanded in vitro using DCs"/>
 <result pre="Moreover, T cells expanded in vitro using DCs pulsed with" exact="total" post="tumor RNA demonstrated a 10- to 20-fold expansion of"/>
 <result pre="T cells expanded in vitro using DCs pulsed with total" exact="tumor" post="RNA demonstrated a 10- to 20-fold expansion of CMV"/>
 <result pre="that CMV-specific T cells can effectively target to kill GBM" exact="tumor" post="cells immunologically in vitro and support the development of"/>
 <result pre="immunotherapy has the potential to induce strong immune responses against" exact="brain tumor" post="in patients with minimal impairment to surrounding normal cells"/>
 <result pre="has the potential to induce strong immune responses against brain" exact="tumor" post="in patients with minimal impairment to surrounding normal cells"/>
 <result pre="survived seven years post-diagnosed with GBM and recovered from CMV" exact="colitis" post="[94]. Following tumor resection, the patient received radiation therapy"/>
 <result pre="post-diagnosed with GBM and recovered from CMV colitis [94]. Following" exact="tumor" post="resection, the patient received radiation therapy and temozolomide combined"/>
 <result pre="therapy and temozolomide combined therapy that was complicated by CMV" exact="colitis" post="and abdominal abscesses. Not receiving adjuvant temozolomide, the patient"/>
 <result pre="survived for two additional years following re-resection. Because the patient’s" exact="tumor" post="was stained positive for CMV antigens of immediately early"/>
 <result pre="the role of CMV and support GBM immunotherapy. 6. Conclusions" exact="Brain" post="diseases, a global human health problem associated with CNS,"/>
 <result pre="serious, irreversible and difficult to treat. CMV is the leading" exact="infectious" post="cause of mental retardation and may be associated with"/>
 <result pre="difficult to treat. CMV is the leading infectious cause of" exact="mental retardation" post="and may be associated with GBM. Currently, a variety"/>
 <result pre="valganciclovir, cidofovir, foscarnet, and valnoctamide) are used to treat CMV" exact="acute" post="infections. However, their efficacy is restricted by side effects,"/>
 <result pre="its prognosis is often poor and still universally detrimental with" exact="short" post="survival times after initial diagnosis. Despite extensive research, only"/>
 <result pre="clinical cases. Regardless of the possible etiologic role of CMV" exact="infections" post="in GBM, the research interest should focus on exploiting"/>
 <result pre="hosts thoroughly to make out how therapeutic approaches influence CMV" exact="infections" post="and improve clinical outcomes for patients. Finally, we should"/>
 <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
 <result pre="for the management of severe traumatic brain injuryJ. Neurotrauma200724S45S5410.1089/neu.2007.999917511545 2.JohnsonG.Traumatic" exact="Brain" post="Injury Survival Guide2004Available online: www.tbiguide.com(accessed on 17 February 2020)"/>
 <result pre="MedicineAvailable online: https://medlineplus.gov/ency/article/001523.htm(accessed on 27 October 2016) 11.General Information about" exact="Adult" post="Brain Tumors. National Cancer Institute (NCI)1442014Available online: http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/Patient/page1/AllPages(accessed on"/>
 <result pre="online: https://medlineplus.gov/ency/article/001523.htm(accessed on 27 October 2016) 11.General Information about Adult" exact="Brain" post="Tumors. National Cancer Institute (NCI)1442014Available online: http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/Patient/page1/AllPages(accessed on 8"/>
 <result pre="27 October 2016) 11.General Information about Adult Brain Tumors. National" exact="Cancer" post="Institute (NCI)1442014Available online: http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/Patient/page1/AllPages(accessed on 8 June 2014) 12.BleekerF.E.MolenaarR.J.LeenstraS.Recent"/>
 <result pre="Neuro-Oncol.2012108112710.1007/s11060-011-0793-0 13.YoungR.M.JamshidiA.DavisG.ShermanJ.H.Current trends in the surgical management and treatment of" exact="adult" post="glioblastomaAnn. Transl. Med.2015312110.3978/j.issn.2305-5839.2015.05.1026207249 14.GallegoO.Nonsurgical treatment of recurrent glioblastomaCurr. Oncol.201522e27310.3747/co.22.243626300678"/>
 <result pre="and treatment of adult glioblastomaAnn. Transl. Med.2015312110.3978/j.issn.2305-5839.2015.05.1026207249 14.GallegoO.Nonsurgical treatment of" exact="recurrent" post="glioblastomaCurr. Oncol.201522e27310.3747/co.22.243626300678 15.Adult Brain Tumors Treatment. National Cancer Institute"/>
 <result pre="glioblastomaAnn. Transl. Med.2015312110.3978/j.issn.2305-5839.2015.05.1026207249 14.GallegoO.Nonsurgical treatment of recurrent glioblastomaCurr. Oncol.201522e27310.3747/co.22.243626300678 15.Adult" exact="Brain" post="Tumors Treatment. National Cancer Institute (NCI)2822014Available online: http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/HealthProfessional/page1/AllPages(accessed on"/>
 <result pre="Transl. Med.2015312110.3978/j.issn.2305-5839.2015.05.1026207249 14.GallegoO.Nonsurgical treatment of recurrent glioblastomaCurr. Oncol.201522e27310.3747/co.22.243626300678 15.Adult Brain" exact="Tumors" post="Treatment. National Cancer Institute (NCI)2822014Available online: http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/HealthProfessional/page1/AllPages(accessed on 8"/>
 <result pre="treatment of recurrent glioblastomaCurr. Oncol.201522e27310.3747/co.22.243626300678 15.Adult Brain Tumors Treatment. National" exact="Cancer" post="Institute (NCI)2822014Available online: http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/HealthProfessional/page1/AllPages(accessed on 8 June 2014) 16.AdamsM.J.CarstensE.B.Ratification"/>
 <result pre="tool for screening antiviral agentsAntimicrob Agents Chemother.2000441588159710.1128/AAC.44.6.1588-1597.200010817714 23.MelnickM.SedghizadehP.P.AllenC.M.JaskollT.Human cytomegalovirus and" exact="mucoepidermoid carcinoma" post="of salivary glands: Cell-specific localization of active viral and"/>
 <result pre="for screening antiviral agentsAntimicrob Agents Chemother.2000441588159710.1128/AAC.44.6.1588-1597.200010817714 23.MelnickM.SedghizadehP.P.AllenC.M.JaskollT.Human cytomegalovirus and mucoepidermoid" exact="carcinoma" post="of salivary glands: Cell-specific localization of active viral and"/>
 <result pre="and mucoepidermoid carcinoma of salivary glands: Cell-specific localization of active" exact="viral" post="and oncogenic signaling proteins is confirmatory of a causal"/>
 <result pre="Seoul, South KoreaBMC Infect. Dis.20191994810.1186/s12879-019-4607-x31703564 28.FowlerK.B.StagnoS.PassR.F.Maternal immunity and prevention of" exact="congenital" post="cytomegalovirus infectionJAMA20032891008101110.1001/jama.289.8.100812597753 29.YamamotoA.Y.Mussi-PinhataM.M.BoppanaS.B.NovakZ.WagatsumaV.M.de Frizzo OliveiraP.DuarteG.BrittW.J.Human cytomegalovirus reinfection is associated"/>
 <result pre="a highly cytomegalovirus-immune maternal populationAm. J. Obstet. Gynecol.2010202297.e1297.e810.1016/j.ajog.2009.11.01820060091 30.StarasS.A.DollardS.C.RadfordK.W.FlandersW.D.PassR.F.CannonM.J.Seroprevalence of" exact="cytomegalovirus infection" post="in the United States, 1988–1994Clin. Infect. Dis.2006431143115110.1086/50817317029132 31.HargettD.ShenkT.E.Experimental human"/>
 <result pre="highly cytomegalovirus-immune maternal populationAm. J. Obstet. Gynecol.2010202297.e1297.e810.1016/j.ajog.2009.11.01820060091 30.StarasS.A.DollardS.C.RadfordK.W.FlandersW.D.PassR.F.CannonM.J.Seroprevalence of cytomegalovirus" exact="infection" post="in the United States, 1988–1994Clin. Infect. Dis.2006431143115110.1086/50817317029132 31.HargettD.ShenkT.E.Experimental human"/>
 <result pre="prevalence of neurological and sensory sequelae and mortality associated with" exact="congenital" post="cytomegalovirus infectionRev. Med Virol.20071735536310.1002/rmv.54417542052 33.KennesonA.CannonM.J.Review and meta-analysis of the"/>
 <result pre="infectionRev. Med Virol.20071735536310.1002/rmv.54417542052 33.KennesonA.CannonM.J.Review and meta-analysis of the epidemiology of" exact="congenital" post="cytomegalovirus (CMV) infectionRev. Med Virol.20071725327610.1002/rmv.53517579921 34.LazzarottoT.GuerraB.GabrielliL.LanariM.LandiniM.P.Update on the prevention,"/>
 <result pre="Med Virol.20071725327610.1002/rmv.53517579921 34.LazzarottoT.GuerraB.GabrielliL.LanariM.LandiniM.P.Update on the prevention, diagnosis and management of" exact="cytomegalovirus infection" post="during pregnancyClin. Microbiol. Infect2011171285129310.1111/j.1469-0691.2011.03564.x21631642 35.PiconeO.Vauloup-FellousC.CordierA.G.GuittonS.SenatM.V.FuchsF.AyoubiJ.M.Grangeot KerosL.BenachiA.A series of 238"/>
 <result pre="Virol.20071725327610.1002/rmv.53517579921 34.LazzarottoT.GuerraB.GabrielliL.LanariM.LandiniM.P.Update on the prevention, diagnosis and management of cytomegalovirus" exact="infection" post="during pregnancyClin. Microbiol. Infect2011171285129310.1111/j.1469-0691.2011.03564.x21631642 35.PiconeO.Vauloup-FellousC.CordierA.G.GuittonS.SenatM.V.FuchsF.AyoubiJ.M.Grangeot KerosL.BenachiA.A series of 238"/>
 <result pre="during pregnancyClin. Microbiol. Infect2011171285129310.1111/j.1469-0691.2011.03564.x21631642 35.PiconeO.Vauloup-FellousC.CordierA.G.GuittonS.SenatM.V.FuchsF.AyoubiJ.M.Grangeot KerosL.BenachiA.A series of 238 cytomegalovirus" exact="primary" post="infections during pregnancy: Description and outcomePrenat. Diagn.20133375175810.1002/pd.411823553686 36.MarsicoC.KimberlinD.W.Congenital cytomegalovirus"/>
 <result pre="pregnancyClin. Microbiol. Infect2011171285129310.1111/j.1469-0691.2011.03564.x21631642 35.PiconeO.Vauloup-FellousC.CordierA.G.GuittonS.SenatM.V.FuchsF.AyoubiJ.M.Grangeot KerosL.BenachiA.A series of 238 cytomegalovirus primary" exact="infections" post="during pregnancy: Description and outcomePrenat. Diagn.20133375175810.1002/pd.411823553686 36.MarsicoC.KimberlinD.W.Congenital cytomegalovirus infection:"/>
 <result pre="and challenges in diagnosis, prevention and treatmentItal. J. Pediatr.2017433810.1186/s13052-017-0358-828416012 37.BoppanaS.B.PassR.F.BrittW.J.StagnoS.AlfordC.A.Symptomatic" exact="congenital" post="cytomegalovirus infection: Neonatal morbidity and mortalityPediatr. Infect. Dis. J.199211939910.1097/00006454-199202000-000071311066"/>
 <result pre="diagnosis, prevention and treatmentItal. J. Pediatr.2017433810.1186/s13052-017-0358-828416012 37.BoppanaS.B.PassR.F.BrittW.J.StagnoS.AlfordC.A.Symptomatic congenital cytomegalovirus infection:" exact="Neonatal" post="morbidity and mortalityPediatr. Infect. Dis. J.199211939910.1097/00006454-199202000-000071311066 38.KylatR.I.KellyE.N.Ford-JonesE.L.Clinical findings and"/>
 <result pre="Dis. J.199211939910.1097/00006454-199202000-000071311066 38.KylatR.I.KellyE.N.Ford-JonesE.L.Clinical findings and adverse outcome in neonates with" exact="symptomatic" post="congenital cytomegalovirus (SCCMV) infectionEur. J. Pediatr.200616577377810.1007/s00431-006-0172-616835757 39.NyholmJ.L.SchleissM.R.Prevention of maternal"/>
 <result pre="J.199211939910.1097/00006454-199202000-000071311066 38.KylatR.I.KellyE.N.Ford-JonesE.L.Clinical findings and adverse outcome in neonates with symptomatic" exact="congenital" post="cytomegalovirus (SCCMV) infectionEur. J. Pediatr.200616577377810.1007/s00431-006-0172-616835757 39.NyholmJ.L.SchleissM.R.Prevention of maternal cytomegalovirus"/>
 <result pre="Women’s Health201022310.2147/IJWH.S578221072294 40.LeungA.K.SauveR.S.DaviesH.D.Congenital cytomegalovirus infectionJ. Natl. Med. Assoc.200395213https://www.ncbi.nlm.nih.gov/pubmed/1274968112749681 41.DreherA.M.AroraN.FowlerK.B.NovakZ.BrittW.J.BoppanaS.B.RossS.A.Spectrum of" exact="disease" post="and outcome in children with symptomatic congenital cytomegalovirus infectionJ."/>
 <result pre="Med. Assoc.200395213https://www.ncbi.nlm.nih.gov/pubmed/1274968112749681 41.DreherA.M.AroraN.FowlerK.B.NovakZ.BrittW.J.BoppanaS.B.RossS.A.Spectrum of disease and outcome in children with" exact="symptomatic" post="congenital cytomegalovirus infectionJ. Pediatrics201416485585910.1016/j.jpeds.2013.12.007 42.SwansonE.C.SchleissM.R.Congenital cytomegalovirus infection: New prospects"/>
 <result pre="Assoc.200395213https://www.ncbi.nlm.nih.gov/pubmed/1274968112749681 41.DreherA.M.AroraN.FowlerK.B.NovakZ.BrittW.J.BoppanaS.B.RossS.A.Spectrum of disease and outcome in children with symptomatic" exact="congenital" post="cytomegalovirus infectionJ. Pediatrics201416485585910.1016/j.jpeds.2013.12.007 42.SwansonE.C.SchleissM.R.Congenital cytomegalovirus infection: New prospects for"/>
 <result pre="cytomegalovirus infection: New prospects for prevention and therapyPediatric Clin.20136033534910.1016/j.pcl.2012.12.008 43.YamamotoA.Y.Mussi-PinhataM.M.IsaacM.D.AmaralF.R.CarvalheiroC.G.AragonD.C.ManfrediA.K.BoppanaS.B.BrittW.J.Congenital" exact="cytomegalovirus infection" post="as a cause of sensorineural hearing loss in a"/>
 <result pre="infection: New prospects for prevention and therapyPediatric Clin.20136033534910.1016/j.pcl.2012.12.008 43.YamamotoA.Y.Mussi-PinhataM.M.IsaacM.D.AmaralF.R.CarvalheiroC.G.AragonD.C.ManfrediA.K.BoppanaS.B.BrittW.J.Congenital cytomegalovirus" exact="infection" post="as a cause of sensorineural hearing loss in a"/>
 <result pre="and therapyPediatric Clin.20136033534910.1016/j.pcl.2012.12.008 43.YamamotoA.Y.Mussi-PinhataM.M.IsaacM.D.AmaralF.R.CarvalheiroC.G.AragonD.C.ManfrediA.K.BoppanaS.B.BrittW.J.Congenital cytomegalovirus infection as a cause of" exact="sensorineural" post="hearing loss in a highly immune populationPediatric Infect. Dis."/>
 <result pre="therapyPediatric Clin.20136033534910.1016/j.pcl.2012.12.008 43.YamamotoA.Y.Mussi-PinhataM.M.IsaacM.D.AmaralF.R.CarvalheiroC.G.AragonD.C.ManfrediA.K.BoppanaS.B.BrittW.J.Congenital cytomegalovirus infection as a cause of sensorineural" exact="hearing loss" post="in a highly immune populationPediatric Infect. Dis. J.201130104310.1097/INF.0b013e31822d964021814153 44.FowlerK.B.BoppanaS.B.Congenital"/>
 <result pre="a highly immune populationPediatric Infect. Dis. J.201130104310.1097/INF.0b013e31822d964021814153 44.FowlerK.B.BoppanaS.B.Congenital cytomegalovirus (CMV)" exact="infection" post="and hearing deficitJ. Clin. Virol.20063522623110.1016/j.jcv.2005.09.01616386462 45.BoppanaS.B.RossS.A.FowlerK.B.Congenital cytomegalovirus infection: Clinical"/>
 <result pre="Infect. Dis.201357S178S18110.1093/cid/cit62924257422 46.Mussi-PinhataM.M.YamamotoA.Y.BritoR.M.M.IsaacM.d.L.de Carvalhoe OliveiraP.F.BoppanaS.BrittW.J.Birth prevalence and natural history of" exact="congenital" post="cytomegalovirus infection in a highly seroimmune populationClin. Infect. Dis.20094952252810.1086/60088219583520"/>
 <result pre="Dis.201357S178S18110.1093/cid/cit62924257422 46.Mussi-PinhataM.M.YamamotoA.Y.BritoR.M.M.IsaacM.d.L.de Carvalhoe OliveiraP.F.BoppanaS.BrittW.J.Birth prevalence and natural history of congenital" exact="cytomegalovirus infection" post="in a highly seroimmune populationClin. Infect. Dis.20094952252810.1086/60088219583520 47.PassR.F.FowlerK.B.BoppanaS.B.BrittW.J.StagnoS.Congenital cytomegalovirus"/>
 <result pre="46.Mussi-PinhataM.M.YamamotoA.Y.BritoR.M.M.IsaacM.d.L.de Carvalhoe OliveiraP.F.BoppanaS.BrittW.J.Birth prevalence and natural history of congenital cytomegalovirus" exact="infection" post="in a highly seroimmune populationClin. Infect. Dis.20094952252810.1086/60088219583520 47.PassR.F.FowlerK.B.BoppanaS.B.BrittW.J.StagnoS.Congenital cytomegalovirus"/>
 <result pre="cytomegalovirus infection in a highly seroimmune populationClin. Infect. Dis.20094952252810.1086/60088219583520 47.PassR.F.FowlerK.B.BoppanaS.B.BrittW.J.StagnoS.Congenital" exact="cytomegalovirus infection" post="following first trimester maternal infection: Symptoms at birth and"/>
 <result pre="infection in a highly seroimmune populationClin. Infect. Dis.20094952252810.1086/60088219583520 47.PassR.F.FowlerK.B.BoppanaS.B.BrittW.J.StagnoS.Congenital cytomegalovirus" exact="infection" post="following first trimester maternal infection: Symptoms at birth and"/>
 <result pre="infection: Symptoms at birth and outcomeJ. Clin. Virol.20063521622010.1016/j.jcv.2005.09.01516368262 48.NassettaL.KimberlinD.WhitleyR.Treatment of" exact="congenital" post="cytomegalovirus infection: Implications for future therapeutic strategiesJ. Antimicrob. Chemother.20096386286710.1093/jac/dkp08319287011"/>
 <result pre="for future therapeutic strategiesJ. Antimicrob. Chemother.20096386286710.1093/jac/dkp08319287011 49.BarbiM.BindaS.CaroppoS.CalvarioA.GerminarioC.BozziA.TanziM.L.VeronesiL.MuraI.PianaA.Multicity Italian study of" exact="congenital" post="cytomegalovirus infectionPediatric Infect. Dis. J.20062515615910.1097/01.inf.0000199261.98769.29 50.CollO.BenoistG.VilleY.WeismanL.E.BotetF.GreenoughA.GibbsR.S.Carbonell-EstranyX.Guidelines on CMV congenital"/>
 <result pre="of congenital cytomegalovirus infectionPediatric Infect. Dis. J.20062515615910.1097/01.inf.0000199261.98769.29 50.CollO.BenoistG.VilleY.WeismanL.E.BotetF.GreenoughA.GibbsR.S.Carbonell-EstranyX.Guidelines on CMV" exact="congenital" post="infectionJ. Perinat. Med.20093743344510.1515/JPM.2009.12719673682 51.GuoY.JiangL.Cytomegalovirus encephalitis in immunocompetent infants: A"/>
 <result pre="Dis. J.20062515615910.1097/01.inf.0000199261.98769.29 50.CollO.BenoistG.VilleY.WeismanL.E.BotetF.GreenoughA.GibbsR.S.Carbonell-EstranyX.Guidelines on CMV congenital infectionJ. Perinat. Med.20093743344510.1515/JPM.2009.12719673682 51.GuoY.JiangL.Cytomegalovirus" exact="encephalitis" post="in immunocompetent infants: A 15-year retrospective study at a"/>
 <result pre="J. Infect. Dis.20198210611010.1016/j.ijid.2019.02.04530844517 52.AbdelazizM.O.OssmannS.KaufmannA.M.LeitnerJ.SteinbergerP.WillimskyG.RafteryM.J.SchönrichG.Development of a human cytomegalovirus (HCMV)-based therapeutic" exact="cancer" post="vaccine uncovers a previously unsuspected viral block of MHC"/>
 <result pre="human cytomegalovirus (HCMV)-based therapeutic cancer vaccine uncovers a previously unsuspected" exact="viral" post="block of MHC class I antigen presentationFront. Immunol.201910177610.3389/fimmu.2019.0177631417555 53.CobbsC.S.HsiehL.SamantaM.GillespieG.Y.BhararaS.KingP.H.NaborsL.B.CobbsC.G.BrittW.J.Human"/>
 <result pre="viral block of MHC class I antigen presentationFront. Immunol.201910177610.3389/fimmu.2019.0177631417555 53.CobbsC.S.HsiehL.SamantaM.GillespieG.Y.BhararaS.KingP.H.NaborsL.B.CobbsC.G.BrittW.J.Human" exact="cytomegalovirus infection" post="and expression in human malignant gliomaCancer Res.2002623347335012067971 54.McFaline-FigueroaJ.R.WenP.Y.The viral"/>
 <result pre="block of MHC class I antigen presentationFront. Immunol.201910177610.3389/fimmu.2019.0177631417555 53.CobbsC.S.HsiehL.SamantaM.GillespieG.Y.BhararaS.KingP.H.NaborsL.B.CobbsC.G.BrittW.J.Human cytomegalovirus" exact="infection" post="and expression in human malignant gliomaCancer Res.2002623347335012067971 54.McFaline-FigueroaJ.R.WenP.Y.The viral"/>
 <result pre="antigen presentationFront. Immunol.201910177610.3389/fimmu.2019.0177631417555 53.CobbsC.S.HsiehL.SamantaM.GillespieG.Y.BhararaS.KingP.H.NaborsL.B.CobbsC.G.BrittW.J.Human cytomegalovirus infection and expression in human" exact="malignant" post="gliomaCancer Res.2002623347335012067971 54.McFaline-FigueroaJ.R.WenP.Y.The viral connection to glioblastomaCurr. Infect. Dis."/>
 <result pre="cytomegalovirus infection and expression in human malignant gliomaCancer Res.2002623347335012067971 54.McFaline-FigueroaJ.R.WenP.Y.The" exact="viral" post="connection to glioblastomaCurr. Infect. Dis. Rep.201719510.1007/s11908-017-0563-z28233187 55.KrenzlinH.BeheraP.LorenzV.PassaroC.ZdiorukM.NowickiM.O.GrauwetK.ZhangH.SkubalM.ItoH.et al.Cytomegalovirus promotes"/>
 <result pre="connection to glioblastomaCurr. Infect. Dis. Rep.201719510.1007/s11908-017-0563-z28233187 55.KrenzlinH.BeheraP.LorenzV.PassaroC.ZdiorukM.NowickiM.O.GrauwetK.ZhangH.SkubalM.ItoH.et al.Cytomegalovirus promotes murine" exact="glioblastoma" post="growth via pericyte recruitment and angiogenesisJ. Clin. Invest.20191301671168310.1172/JCI12337530855281 56.GriffithsP.New"/>
 <result pre="for glioblastomaN. Engl. J. Med.200535298799610.1056/NEJMoa04333015758009 61.OrnaghiS.HsiehL.S.BordeyA.VerganiP.PaidasM.J.van den PolA.N.Valnoctamide Inhibits Cytomegalovirus" exact="Infection" post="in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain"/>
 <result pre="J. Med.200535298799610.1056/NEJMoa04333015758009 61.OrnaghiS.HsiehL.S.BordeyA.VerganiP.PaidasM.J.van den PolA.N.Valnoctamide Inhibits Cytomegalovirus Infection in Developing" exact="Brain" post="and Attenuates Neurobehavioral Dysfunctions and Brain AbnormalitiesJ. Neurosci.2017376877689310.1523/JNEUROSCI.0970-17.201728630251 62.KrishnaB.A.WillsM.R.SinclairJ.H.Advances"/>
 <result pre="PolA.N.Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral" exact="Dysfunctions" post="and Brain AbnormalitiesJ. Neurosci.2017376877689310.1523/JNEUROSCI.0970-17.201728630251 62.KrishnaB.A.WillsM.R.SinclairJ.H.Advances in the treatment of"/>
 <result pre="Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and" exact="Brain" post="AbnormalitiesJ. Neurosci.2017376877689310.1523/JNEUROSCI.0970-17.201728630251 62.KrishnaB.A.WillsM.R.SinclairJ.H.Advances in the treatment of cytomegalovirusBr. Med."/>
 <result pre="KampenJ.J.Emergence and persistence of letermovir-resistant cytomegalovirus in a patient with" exact="primary" post="immunodeficiencyOpen Forum Infect. Dis.20196ofz37510.1093/ofid/ofz37531660414 64.LinA.MaloyM.SuY.BhattV.DeRespirisL.GriffinM.LauC.ProliA.BarkerJ.ShafferB.et al.Letermovir for primary and"/>
 <result pre="patient with primary immunodeficiencyOpen Forum Infect. Dis.20196ofz37510.1093/ofid/ofz37531660414 64.LinA.MaloyM.SuY.BhattV.DeRespirisL.GriffinM.LauC.ProliA.BarkerJ.ShafferB.et al.Letermovir for" exact="primary" post="and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant"/>
 <result pre="primary immunodeficiencyOpen Forum Infect. Dis.20196ofz37510.1093/ofid/ofz37531660414 64.LinA.MaloyM.SuY.BhattV.DeRespirisL.GriffinM.LauC.ProliA.BarkerJ.ShafferB.et al.Letermovir for primary and" exact="secondary" post="cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world"/>
 <result pre="transplant recipientsTranspl. Infect. Dis.2019e1316610.1111/tid.1316631487755 66.VeitT.MunkerD.KaukeT.ZollerM.MichelS.CeelenF.SchiopuS.BartonJ.ArnoldP.MilgerK.et al.Letermovir for difficult to treat" exact="cytomegalovirus infection" post="in lung transplant recipientsTransplantation201910.1097/TP.000000000000288631385924 67.ChemalyR.F.UllmannA.J.StoelbenS.RichardM.P.BornhäuserM.GrothC.EinseleH.SilvermanM.MullaneK.M.BrownJ.et al.Letermovir for cytomegalovirus prophylaxis"/>
 <result pre="recipientsTranspl. Infect. Dis.2019e1316610.1111/tid.1316631487755 66.VeitT.MunkerD.KaukeT.ZollerM.MichelS.CeelenF.SchiopuS.BartonJ.ArnoldP.MilgerK.et al.Letermovir for difficult to treat cytomegalovirus" exact="infection" post="in lung transplant recipientsTransplantation201910.1097/TP.000000000000288631385924 67.ChemalyR.F.UllmannA.J.StoelbenS.RichardM.P.BornhäuserM.GrothC.EinseleH.SilvermanM.MullaneK.M.BrownJ.et al.Letermovir for cytomegalovirus prophylaxis"/>
 <result pre="Engl. J. Med.20193811136114710.1056/NEJMoa171465631532960 70.PapanicolaouG.A.SilveiraF.P.LangstonA.A.PereiraM.R.AveryR.K.UknisM.WijatykA.WuJ.BoeckhM.MartyF.M.et al.Maribavir for refractory or resistant cytomegalovirus" exact="infections" post="in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging,"/>
 <result pre="oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantationBiol." exact="Blood" post="Marrow Transpl.20192536938110.1016/j.bbmt.2018.09.03830292744 74.EvansD.MarquezS.M.PaceN.R.RNase P: Interface of the RNA and"/>
 <result pre="PPhilos. Trans. R. Soc. B Biol. Sci.20113662936294110.1098/rstb.2011.0142 77.LiW.ShengJ.XuM.VuG.P.YangZ.LiuY.SunX.TrangP.LuS.LiuF.Inhibition of murine" exact="cytomegalovirus infection" post="in animals by RNase P-associated external guide sequencesMol. Ther."/>
 <result pre="Trans. R. Soc. B Biol. Sci.20113662936294110.1098/rstb.2011.0142 77.LiW.ShengJ.XuM.VuG.P.YangZ.LiuY.SunX.TrangP.LuS.LiuF.Inhibition of murine cytomegalovirus" exact="infection" post="in animals by RNase P-associated external guide sequencesMol. Ther."/>
 <result pre="77.LiW.ShengJ.XuM.VuG.P.YangZ.LiuY.SunX.TrangP.LuS.LiuF.Inhibition of murine cytomegalovirus infection in animals by RNase P-associated" exact="external" post="guide sequencesMol. Ther. Nucleic Acids20171532233210.1016/j.omtn.2017.10.00729246310 78.LiW.LiuY.WangY.LiR.TrangP.TangW.YangZ.WangY.SunX.XingX.et al.Engineered RNase P"/>
 <result pre="Nucleic Acids20171532233210.1016/j.omtn.2017.10.00729246310 78.LiW.LiuY.WangY.LiR.TrangP.TangW.YangZ.WangY.SunX.XingX.et al.Engineered RNase P ribozymes effectively inhibit the" exact="infection" post="of murine cytomegalovirus in animalsTheranostics201885634564410.7150/thno.2777630555569 79.DengQ.LiuY.LiX.YanB.SunX.TangW.TrangP.YangZ.GongH.WangY.et al.Inhibition of human"/>
 <result pre="cytomegalovirus major capsid protein expression and replication by ribonuclease P-associated" exact="external" post="guide sequencesRNA20192564565510.1261/rna.069682.11830803999 80.ChenY.-C.ShengJ.TrangP.LiuF.Potential application of the CRISPR/Cas9 system against"/>
 <result pre="al.Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential" exact="viral" post="genePLoS ONE201813e019260210.1371/journal.pone.019260229447206 84.LiT.HuangS.JiangW.Z.WrightD.SpaldingM.H.WeeksD.P.YangB.TAL nucleases (TALNs): Hybrid proteins composed of"/>
 <result pre="immunotherapy directed against human cytomegalovirus as a novel approach for" exact="glioblastoma" post="treatmentOncoimmunology20143e2938110.4161/onci.2938125083342 89.SchuesslerA.WalkerD.G.KhannaR.Cytomegalovirus as a novel target for immunotherapy of"/>
 <result pre="glioblastoma treatmentOncoimmunology20143e2938110.4161/onci.2938125083342 89.SchuesslerA.WalkerD.G.KhannaR.Cytomegalovirus as a novel target for immunotherapy of" exact="glioblastoma" post="multiformeFront. Oncol.2014427510.3389/fonc.2014.0027525340042 90.FergusonS.D.SrinivasanV.M.GhaliM.G.HeimbergerA.B.Cytomegalovirus-targeted immunotherapy and glioblastoma: Hype or hope?Immunotherapy2016841342310.2217/imt.16.226973123"/>
 <result pre="and opportunitiesJ. Neurooncol.201512346547110.1007/s11060-015-1734-025682092 92.NairS.K.De LeonG.BoczkowskiD.SchmittlingR.XieW.StaatsJ.LiuR.JohnsonL.A.WeinholdK.ArcherG.E.et al.Recognition and killing of autologous," exact="primary" post="glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T"/>
 <result pre="opportunitiesJ. Neurooncol.201512346547110.1007/s11060-015-1734-025682092 92.NairS.K.De LeonG.BoczkowskiD.SchmittlingR.XieW.StaatsJ.LiuR.JohnsonL.A.WeinholdK.ArcherG.E.et al.Recognition and killing of autologous, primary" exact="glioblastoma" post="tumor cells by human cytomegalovirus pp65-specific cytotoxic T cellsClin."/>
 <result pre="Neurooncol.201512346547110.1007/s11060-015-1734-025682092 92.NairS.K.De LeonG.BoczkowskiD.SchmittlingR.XieW.StaatsJ.LiuR.JohnsonL.A.WeinholdK.ArcherG.E.et al.Recognition and killing of autologous, primary glioblastoma" exact="tumor" post="cells by human cytomegalovirus pp65-specific cytotoxic T cellsClin. Cancer"/>
 <result pre="glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cellsClin." exact="Cancer" post="Res.2014202684269410.1158/1078-0432.CCR-13-326824658154 93.BatichK.A.ReapE.A.ArcherG.E.Sanchez-PerezL.NairS.K.SchmittlingR.J.NorbergP.XieW.HerndonJ.E.2ndHealyP.et al.Long-term survival in glioblastoma with cytomegalovirus pp65-targeted"/>
 <result pre="pp65-specific cytotoxic T cellsClin. Cancer Res.2014202684269410.1158/1078-0432.CCR-13-326824658154 93.BatichK.A.ReapE.A.ArcherG.E.Sanchez-PerezL.NairS.K.SchmittlingR.J.NorbergP.XieW.HerndonJ.E.2ndHealyP.et al.Long-term survival in" exact="glioblastoma" post="with cytomegalovirus pp65-targeted vaccinationClin. Cancer Res.2017231898190910.1158/1078-0432.CCR-16-205728411277 94.LamanoJ.B.Quaggin-SmithJ.A.HorbinskiC.M.TateM.C.GrimmS.A.KumthekarP.U.BlochO.Long-term glioblastoma survival"/>
 <result pre="Res.2014202684269410.1158/1078-0432.CCR-13-326824658154 93.BatichK.A.ReapE.A.ArcherG.E.Sanchez-PerezL.NairS.K.SchmittlingR.J.NorbergP.XieW.HerndonJ.E.2ndHealyP.et al.Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccinationClin." exact="Cancer" post="Res.2017231898190910.1158/1078-0432.CCR-16-205728411277 94.LamanoJ.B.Quaggin-SmithJ.A.HorbinskiC.M.TateM.C.GrimmS.A.KumthekarP.U.BlochO.Long-term glioblastoma survival following recovery from cytomegalovirus colitis:"/>
 <result pre="survival in glioblastoma with cytomegalovirus pp65-targeted vaccinationClin. Cancer Res.2017231898190910.1158/1078-0432.CCR-16-205728411277 94.LamanoJ.B.Quaggin-SmithJ.A.HorbinskiC.M.TateM.C.GrimmS.A.KumthekarP.U.BlochO.Long-term" exact="glioblastoma" post="survival following recovery from cytomegalovirus colitis: A case reportJ."/>
 <result pre="case reportJ. Clin. Neurosci.201964182110.1016/j.jocn.2019.03.05130948314 ijms-21-01376-t001_Table 1Table 1 Major types of" exact="brain diseases." post="Brain Disease Brain Injury Mental Disorder Neurodegenerative Disease Mental"/>
 <result pre="Clin. Neurosci.201964182110.1016/j.jocn.2019.03.05130948314 ijms-21-01376-t001_Table 1Table 1 Major types of brain diseases." exact="Brain" post="Disease Brain Injury Mental Disorder Neurodegenerative Disease Mental Retardation"/>
 <result pre="Neurosci.201964182110.1016/j.jocn.2019.03.05130948314 ijms-21-01376-t001_Table 1Table 1 Major types of brain diseases. Brain" exact="Disease" post="Brain Injury Mental Disorder Neurodegenerative Disease Mental Retardation Brain"/>
 <result pre="ijms-21-01376-t001_Table 1Table 1 Major types of brain diseases. Brain Disease" exact="Brain" post="Injury Mental Disorder Neurodegenerative Disease Mental Retardation Brain Tumor"/>
 <result pre="Major types of brain diseases. Brain Disease Brain Injury Mental" exact="Disorder" post="Neurodegenerative Disease Mental Retardation Brain Tumor Example Blunt trauma"/>
 <result pre="of brain diseases. Brain Disease Brain Injury Mental Disorder Neurodegenerative" exact="Disease" post="Mental Retardation Brain Tumor Example Blunt trauma Psychoneurosis, schizophrenia,"/>
 <result pre="brain diseases. Brain Disease Brain Injury Mental Disorder Neurodegenerative Disease" exact="Mental Retardation" post="Brain Tumor Example Blunt trauma Psychoneurosis, schizophrenia, substance (e.g.,"/>
 <result pre="diseases. Brain Disease Brain Injury Mental Disorder Neurodegenerative Disease Mental" exact="Retardation" post="Brain Tumor Example Blunt trauma Psychoneurosis, schizophrenia, substance (e.g.,"/>
 <result pre="Brain Disease Brain Injury Mental Disorder Neurodegenerative Disease Mental Retardation" exact="Brain" post="Tumor Example Blunt trauma Psychoneurosis, schizophrenia, substance (e.g., drug,"/>
 <result pre="Disease Brain Injury Mental Disorder Neurodegenerative Disease Mental Retardation Brain" exact="Tumor" post="Example Blunt trauma Psychoneurosis, schizophrenia, substance (e.g., drug, alcohol)"/>
 <result pre="schizophrenia, substance (e.g., drug, alcohol) addiction, Parkinson’s disease, Alzheimer’s disease," exact="Huntington’s disease," post="Spinocerebellar ataxia, Spinal muscular atrophy Intellectual disability, general learning"/>
 <result pre="(e.g., drug, alcohol) addiction, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease," exact="Spinocerebellar ataxia," post="Spinal muscular atrophy Intellectual disability, general learning disability Primary"/>
 <result pre="alcohol) addiction, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, Spinocerebellar ataxia," exact="Spinal muscular atrophy" post="Intellectual disability, general learning disability Primary brain tumor, secondary"/>
 <result pre="addiction, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, Spinocerebellar ataxia, Spinal" exact="muscular atrophy" post="Intellectual disability, general learning disability Primary brain tumor, secondary"/>
 <result pre="Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, Spinocerebellar ataxia, Spinal muscular" exact="atrophy" post="Intellectual disability, general learning disability Primary brain tumor, secondary"/>
 <result pre="disease, Alzheimer’s disease, Huntington’s disease, Spinocerebellar ataxia, Spinal muscular atrophy" exact="Intellectual disability," post="general learning disability Primary brain tumor, secondary or metastatic"/>
 <result pre="disease, Huntington’s disease, Spinocerebellar ataxia, Spinal muscular atrophy Intellectual disability," exact="general learning disability" post="Primary brain tumor, secondary or metastatic brain tumor, glioblastoma"/>
 <result pre="Huntington’s disease, Spinocerebellar ataxia, Spinal muscular atrophy Intellectual disability, general" exact="learning disability" post="Primary brain tumor, secondary or metastatic brain tumor, glioblastoma"/>
 <result pre="Spinocerebellar ataxia, Spinal muscular atrophy Intellectual disability, general learning disability" exact="Primary" post="brain tumor, secondary or metastatic brain tumor, glioblastoma [11,12]"/>
 <result pre="ataxia, Spinal muscular atrophy Intellectual disability, general learning disability Primary" exact="brain tumor," post="secondary or metastatic brain tumor, glioblastoma [11,12] Associated factor"/>
 <result pre="muscular atrophy Intellectual disability, general learning disability Primary brain tumor," exact="secondary" post="or metastatic brain tumor, glioblastoma [11,12] Associated factor Hematomas,"/>
 <result pre="Intellectual disability, general learning disability Primary brain tumor, secondary or" exact="metastatic" post="brain tumor, glioblastoma [11,12] Associated factor Hematomas, blood clots,"/>
 <result pre="disability, general learning disability Primary brain tumor, secondary or metastatic" exact="brain tumor," post="glioblastoma [11,12] Associated factor Hematomas, blood clots, contusions, cerebral"/>
 <result pre="learning disability Primary brain tumor, secondary or metastatic brain tumor," exact="glioblastoma" post="[11,12] Associated factor Hematomas, blood clots, contusions, cerebral edema,"/>
 <result pre="brain tumor, glioblastoma [11,12] Associated factor Hematomas, blood clots, contusions," exact="cerebral edema," post="concussions, stroke Environment, stress, genetics, physiology, neurobiochemical state Aging,"/>
 <result pre="[11,12] Associated factor Hematomas, blood clots, contusions, cerebral edema, concussions," exact="stroke" post="Environment, stress, genetics, physiology, neurobiochemical state Aging, genetics Genetics,"/>
 <result pre="birth, malnutrition, exposure to certain diseases or toxins, cytomegalovirus (CMV)" exact="infection" post="Largely unclear, maybe genetics, radiation, CMV infection Main symptom"/>
 <result pre="toxins, cytomegalovirus (CMV) infection Largely unclear, maybe genetics, radiation, CMV" exact="infection" post="Main symptom Vomiting, nausea, speech difficulty, ear bleeding, numbness,"/>
 <result pre="problem [1,2] Depression, anxiety, agitation, delusion, stress, obsession, adaptation difficulty," exact="emotional" post="reaction, odd behavior, retarded intellectual development [3,4] Memory loss,"/>
 <result pre="apathy, tremor, rigid, unstable posture, speech difficulty, movement retardation, facial" exact="nerve" post="paralysis, disorientation, intellectual problem, mood change [5,6] Delayed learning,"/>
 <result pre="retardation, facial nerve paralysis, disorientation, intellectual problem, mood change [5,6]" exact="Delayed" post="learning, self- care difficulty, poor planning ability, behavioral and"/>
</results>
